Bionano Genomics, Inc.

Listed Company

BNGOCIK 0001411690NasdaqNon-AcceleratedSmaller ReportingLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$28.51M

Net Income

$-26.39M

Total Assets

$73.58M

Equity

$44.42M

Shares Out

11.47M

Op. Cash Flow

$-16.30M

BNGO$1.16−65.83% · past yearDBEQ Basic

Daily closing prices

Business

Bionano Genomics provides optical genome mapping (OGM) solutions, nucleic acid isolation and purification systems, genome analysis software, and diagnostic testing services for structural variant detection in research and clinical applications. The company develops and sells the Saphyr and Stratys OGM instruments, consumables, reagents, the Ionic Purification system, and VIA software for data interpretation. Operating segments include OGM systems and consumables, nucleic acid isolation products, software solutions, and Bionano Laboratories diagnostic services. The company markets globally through direct sales in North America and Europe and via distributors in Asia-Pacific and other regions.

Summary from 10-K filed 2026-03-23

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	29	31	36	28	18
Total cost of revenue	15	30	27	22	14
Research and development	11	25	54	49	22
Selling, general and administrative	35	52	93	89	58
Intangible assets and other long-lived assets impairment	0	20	—	—	—
Restructuring costs	0	8	741,000	—	—
Total operating expenses	47	104	225	138	81
Loss from operations	−33	−104	−215	−132	−77
Interest income	1	2	3	2	236,000
Other income (expense)	6	−10	−20	−223,000	−59,000
Total other income (expense)	7	−8	−17	986,000	−1
Loss before income taxes	−26	−112	−232	−131	−78
Provision for income taxes	−67,000	−33,000	−62,000	−2	6
Net loss	−26	−112	−232	−133	−72
Net loss per share, basic (in dollars per share)	−4.85	−88.13	−408.6	−4.58	−0.26
Weighted-average common shares outstanding, basic (in shares)	5	1	569,000	29	277
Net loss per share, diluted (in dollars per share)	−4.85	−88.13	−408.6	−4.58	−0.26
Weighted-average common shares outstanding, diluted (in shares)	5	1	569,000	29	277

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3	9	18	5	25
Investments	16	302,000	49	108	226
Accounts receivable, net	5	5	9	7	5
Inventory	5	11	23	30	—
Prepaid expenses and other current assets	5	3	6	7	4
Restricted investments	10	11	35	0	—
Total current assets	45	39	140	157	272
Restricted cash	0	400,000	400,000	400,000	0
Property and equipment, net	15	19	23	18	10
Operating lease right-of-use assets	3	2	6	7	7
Finance lease right-of-use assets	3	3	4	4	4
Intangible assets, net	4	10	34	41	27
Other long-term assets	3	3	7	2	749,000
Total assets	74	77	214	308	377
Accounts payable	6	7	10	13	11
Accrued expenses	5	6	8	11	9
Contract liabilities	967,000	1	783,000	871,000	—
Operating lease liability	697,000	3	2	2	1
Finance lease liability	249,000	260,000	272,000	285,000	299,000
Convertible debentures payable (at fair value)	10	20	70	0	—
Total current liabilities	23	37	100	36	22
Operating lease liability, net of current portion	2	145,000	4	6	5
Finance lease liability, net of current portion	3	4	4	4	4
Long-term contract liabilities	249,000	267,000	154,000	127,000	—
Total liabilities	29	41	118	58	40
Commitments and contingencies (Note 11)	—	—	—	—	—
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.0001 par value; 400,000,000 shares authorized at December 31, 2025 and 2024; 10,740,200 and 1,865,400 shares issued and outstanding at December 31, 2025 and 2024, respectively	1,000	0	0	3,000	29,000
Additional paid-in capital	764	729	677	599	554
Accumulated deficit	−720	−693	−581	−349	−216
Accumulated other comprehensive income	17,000	27,000	23,000	−1	−539,000
Total stockholders equity	44	35	96	249	337
Total liabilities and stockholders equity	74	77	214	308	377

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization expense	10	14	14	10	3
Inventory write-offs	0	7	0	—	0
Amortization of financing lease right-of-use asset	204,000	204,000	204,000	219,000	19,000
Accretion of interest on securities	−976,000	−1	−539,000	638,000	—
Net realized loss on investments	0	14,000	23,000	66,000	0
Non-cash lease expense	893,000	122,000	—	—	—
Gain on lease modification	−450,000	−73,000	0	—	—
Stock-based compensation	5	10	15	22	10
Cost of leased equipment sold to customer	704,000	361,000	382,000	204,000	568,000
Change in fair value of contingent consideration	0	−11	−1	316,000	66,000
Change in fair value of convertible debentures, convertible notes payable and option liability	−5	−8	−575,000	0	—
Loss on issuance of convertible debentures	0	2	19	—	—
Gain on High Trail extinguishment	0	−4	0	—	—
Loss on extinguishment of convertible debentures payable	0	7	0	—	—
Disposal of internal-use software	0	1	—	—	—
Intangible assets and other long-lived assets impairment	0	18	0	—	—
Long-lived assets held for sale impairment	0	425,000	0	—	—
Right-of-use-asset impairment	0	1	0	—	—
Disposal of property and equipment	300,000	1	0	—	—
Accounts receivable	−448,000	4	−2	−2	−493,000
Inventory	5	−587,000	−4	−24	−16
Prepaid expenses and other current assets	−2	2	1	−3	−1
Other long-term assets	60,000	5	—	—	—
Accounts payable	−1	−3	−2	2	7
Accrued expenses, contract liabilities, and lease liabilities, net	−580,000	−2	−3	366,000	4
Net cash used in operating activities	−16	−69	−125	−125	−72
Purchases of property and equipment	0	−103,000	−2	−2	—
Purchase of available for sale securities	−242	−233	−111	−84	−313
Sale and maturities of available for sale securities	229	307	137	201	86
Net cash provided by (used in) investing activities	−13	74	24	83	−278
Principal payments of financing lease liability	−71,000	−58,000	−47,000	−36,000	−5,000
Proceeds from sale of common stock and warrants	31	44	58	23	—
Offering expenses on sale of common stock and warrants	−2	−3	−1	−578,000	−2
Proceeds from sale of common stock under employee stock purchase plan	0	11,000	107,000	—	—
Proceeds from warrant and option exercises	9,000	4,000	23,000	—	—
Proceeds from issuance of convertible debentures	0	18	80	—	0
Payments on High Trail notes	0	−61	−9	—	—
Payments on convertible debentures	−5	−5	0	0	—
Debt issuance costs on sale of convertible debentures	0	−2	−5	0	—
Payments of retirement fees for redemption of High Trail notes	0	−5	0	—	—
Net cash provided by (used in) financing activities	24	−14	114	23	336
Effect of exchange rates on cash and cash equivalents and restricted cash	−11,000	−7,000	65,000	−38,000	0
Net decrease in cash and cash equivalents and restricted cash	−5	−9	13	−19	−14
Cash paid for interest	2	11	2	298,000	2
Cash paid for operating lease liabilities	2	3	3	2	447,000
Transfer of instruments and servers from inventory into property and equipment, net	757,000	5	11	—	—
Issuance of common stock for convertible debentures payable	350,000	0	—	—	—
Accrued liability for fees to be paid in common stock	0	2	0	—	—
Fees paid in common stock	2	0	—	—	—
Operating lease liabilities resulting from obtaining right-of-use assets	3	0	0	517,000	5
Non-cash Fill-Up Amount	0	491,000	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Bionano Genomics, Inc.'s CIK number?

Bionano Genomics, Inc.'s SEC CIK number is 0001411690 (1411690). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Bionano Genomics, Inc.'s SEC filings?

All of Bionano Genomics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Bionano Genomics, Inc. last report earnings?

Bionano Genomics, Inc. (BNGO) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001411690-26-000027). This is Bionano Genomics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Bionano Genomics, Inc.'s most recent earnings 8-K?

Bionano Genomics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001411690-26-000027. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Bionano Genomics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →